- Doctors | Friday, February 6
- Doctors | Saturday, February 7
- Nurses | Saturday, February 7
| 11:30 – 12:00 | Registration | |
| Diagnostics of lung cancer Chairpersons: Denis Baričević, Dražena Srdić | ||
| 12:00 – 12:05 | Opening remarks | |
| 12:05 – 12:20 | Kristina Krpina | Update on lung cancer screening |
| 12:20 – 12:35 | Ana Marija Alduk | Peripheral nodules – outside in |
| 12:35 – 12:50 | Aleš Rozman | Peripheral nodules – inside out |
| 12:50 – 13:05 | Silvana Smojver Ježek | What can we get from cytology samples? |
| 13:05 – 13:20 | Monika Ulamec | Importance of STAS in thoracic oncology |
  Perioperative treatment of NSCLC Chairpersons: Marko Jakopović, Lela Bitar | ||
| 13:20 – 13:35 | Lidija Ljubičić | Perioperative immunotherapy treatment in NSCLC patients without actionable mutations |
| 13:35 – 13:50 | Maximilian Hochmair | Perioperative treatment in patients with NSCLC and actionable mutations |
| 13:50 – 14:05 | Marko Jakopović | Can we tailor perioperative treatment? |
| 14:05 – 14:25 | Coffee break | |
| 14:25 – 14:55 | Satellite symposium MSD | |
 Targeted treatments Chairpersons: Davorin Radosavljević, Sanja Pleština | ||
| 14:55 – 15:10 | Ivana Canjko | Can we tailor upfront treatment of ALK positive NSCLC? |
| 15:10 – 15:25 | Katja Mohorčić | The right upfront treatment of EGFR positive NSCLC – do we know the answer? |
| 15:25 – 15:40 | Urška Janžić | Importance of co-mutations in NSCLC |
| 15:40 – 15:55 | Lela Bitar | HER2 NSCLC – can we do better? |
| 15:55 – 16:10 | Jasna Radić | KRAS positive lung cancer – what are the options? |
| 16:10 – 16:25 | Sanja Pleština | New targets in NSCLC |
| 16:25 – 16:40 | Tihana Pavić | Concomitant radiotherapy and targeted treatments or IO |
| 16:40 – 17:00 | Coffee break | |
| Translational medicine Chairpersons: Marko Jakopović, Urška Janžić | ||
| 17:00 – 17:15 | Rosa Karlić | What is the role of microbiota in thoracic oncology |
| 17:15 – 17:30 | Marina Popović | When do we need testing for germ-line mutations? |
| 17:30 – 17:45 | Petar Ozretić | Epitranstricptomics: RNA modifications and their regulators as a source of new cancer biomarkers and therapeutic targets |
| 17:45 – 18:00 | Tajana Silovski | What can we learn from breast cancer treatment? |
| Palliative care Chairpersons: Ana Bačelić Gabelica, Katja Mohorčić | ||
| 18:00 – 18:15 | Latinka Basara | Psychological approach to end-of-life care |
| 18:15 – 18:30 | Ivo Planinc | Cardio-oncology |
| 18:30 – 18:45 | Tomi Kovačević | Can we define unfit patients for radical treatments (surgery, radiotherapy, chemotherapy…)? |
| 18:45 – 19:00 | Jasna But Hadžić | The role of SBRT in metastatic lung cancer |
| 20:30 | Dinner | |
| 08:30 – 09:00 | Registration | |
| Chairpersons: Marko Jakopović, Tihana Pavić | ||
| 09:00 – 09:15 | Goran Madžarac | Robotic thoracic surgery |
| 09:15 – 09:30 | Thomas Klikovits | Selective vs complete nodal dissection in radical thoracic surgery |
| 09:30 – 09:45 | Bojan Zarić | Treatment of unresectable stage III NSCLC (PACIFIC and beyond) |
| 09:45 – 10:15 | Satellite symposium ROCHE Lela Bitar, Fran Seiwerth | Redefining ES-SCLC Treatment: Where We Are Today and Where We’re Going |
| 10:15 – 10:45 | Satellite symposium AstraZeneca | |
| 10:45 – 11:15 | Coffee break | |
 Immunotherapy Chairpersons: Bojan Zarić, Sanja Pleština | ||
| 11:15 – 11:30 | Dražena Srdić | Can we combine immunotherapy with targeted agents? |
| 11:30 – 11:45 | Jelena Spasić | Immunotherapy – how long is enough? |
| 11:45 – 12:00 | Fran Seiwerth | Immunotherapy – do we know the right dose? |
| 12:00 – 12:15 | Vide Popović | Is there a role for rechallenge of IO? |
| 12:15 – 12:30 | Suzana Mladinov | Who should not receive immunotherapy today? |
| 12:30 – 12:45 | Marta Koršić | Efficacy of IO regarding smoking status |
| 12:45 – 13:00 | Dragan Trivanović | Can we improve patient care in thoracic oncology – experience from county hospital |
| 13:00 – 13:15 | Marijo Boban | What is new in SCLC? |
| 13:15 – 13:30 | Closing remarks | |
| 13:45 | Lunch | |
| 09:00 – 09:20 | Tihana Gašpert | Adherence in cancer patients and the importance of a non-pharmacological approach – bibliotherapy |
| 09:20 – 09:40 | Petra Popović | Subcutaneous Administration of Therapy – Experience from Pula |
| 09:40 – 10:10 | Satellite symposium AstraZeneca | |
| 10:10 – 10:40 | Coffee break | |
| 10:40 – 11:00 | Maria Paula Požgaj, Marija Škrtić | Adverse Events of Immunotherapy and Nursing Documentation |
| 11:00 – 11:20 | Ivana Lukić Franolić | Lung Cancer: Multiple Faces of the Disease – Nursing Care Through Two Case Reports |
| 11:20 – 11:40 | Sandra Karabatić | Challenges Along the Patient’s Journey – A Case Report |
| 11:40 – 12:00 | Aleksandra Trupković | Interventional Bronchoscopy in Lung Cancer |
| 12:00 – 12:30 | Satellite symposium MSD | |
| 12:30 – 12:50 | Anela Muratović | Experience with Targeted Therapy in Lung Cancer in Slovenia: Adverse Events and Nursing Care – A Case Report |
| 13:00 | Lunch | |